Literature DB >> 7517405

Inhibition of angiogenesis by tissue inhibitor of metalloproteinase.

M D Johnson1, H R Kim, L Chesler, G Tsao-Wu, N Bouck, P J Polverini.   

Abstract

Matrix proteases play a critical role in cell invasion and migration, including the process of angiogenesis. The ability of specific factors to induce angiogenic responses correlates with their stimulation of matrix protease synthesis and release. Using an in vivo angiogenesis assay, the endothelial cell response to known angiogenic factors, basic fibroblast growth factor (bFGF) and adipocyte conditioned medium, was blocked by an inhibitor of matrix metalloproteinase activity, TIMP-1. The TIMP effect was mediated, at least in part, through the inhibition of endothelial cell migration, as determined by the ability of TIMP to block chemotaxis in a Boyden chamber assay. These results indicate that the inhibition of migration is a direct effect on the endothelial cells and does not require accessory cells. An additional observation was that the RNA levels for TIMP were significantly reduced in differentiated adipocytes, compared to undifferentiated F442A controls. Therefore, the acquisition of an angiogenic phenotype may involve not only the induction of positive factors, but also the suppression of angiogenesis inhibitors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517405     DOI: 10.1002/jcp.1041600122

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  46 in total

1.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.

Authors:  L Guedez; A J McMarlin; D W Kingma; T A Bennett; M Stetler-Stevenson; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 3.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 4.  A role for antiangiogenic therapy in breast cancer.

Authors:  Marsha A Moses; Jay Harper; Cecilia A Fernández
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

5.  Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin.

Authors:  K Mori; A Ando; P Gehlbach; D Nesbitt; K Takahashi; D Goldsteen; M Penn; C T Chen; K Mori; M Melia; S Phipps; D Moffat; K Brazzell; G Liau; K H Dixon; P A Campochiaro
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

6.  Exosomes from retinal astrocytes contain antiangiogenic components that inhibit laser-induced choroidal neovascularization.

Authors:  Amir Reza Hajrasouliha; Guomin Jiang; Qingxian Lu; Huayi Lu; Henry J Kaplan; Huang-Ge Zhang; Hui Shao
Journal:  J Biol Chem       Date:  2013-08-07       Impact factor: 5.157

7.  Correlation between the COL4A3, MMP-9, and TIMP-1 polymorphisms and risk of keratoconus.

Authors:  Ramin Saravani; Davood Yari; Samira Saravani; Farzaneh Hasanian-Langroudi
Journal:  Jpn J Ophthalmol       Date:  2017-02-14       Impact factor: 2.447

Review 8.  The role of alphav integrins during angiogenesis.

Authors:  B P Eliceiri; D A Cheresh
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

9.  Matrix metalloproteinase inhibition influences aspects of photoperiod stimulated ovarian recrudescence in Siberian hamsters.

Authors:  Asha Shahed; Jamie J Simmons; Sydney L Featherstone; Kelly A Young
Journal:  Gen Comp Endocrinol       Date:  2015-04-21       Impact factor: 2.822

10.  Localization of messenger RNA for tissue inhibitor of metalloproteinases-1 and type IV collagenases/gelatinases in monkey hepatocellular carcinomas.

Authors:  C K Lindsay; U P Thorgeirsson
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.